Social Risks-Focused Lifestyle Intervention to Reduce Preeclampsia (SAIL)

Preeclampsia Clinical Trial

— SAIL  

Official title:

Social Risks-Focused Lifestyle Intervention to Reduce Preeclampsia in AA Women

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04958057
• Other study ID #: PRO00041206
• Secondary ID: 847482
• Status: Recruiting
• Phase: N/A
• Start date: March 28, 2022
• Est. completion date: September 30, 2024

Study information

• Verified date: August 2023
• Source: Medical College of Wisconsin
• Contact: Anna Palatnik, MD
• Phone: 414-805-6627
• Email: apalatnik[@]mcw.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Preeclampsia is a disease of pregnancy and first few weeks after birth. It is diagnosed as new onset of high blood pressure and injury to organs such as kidneys, liver, and brain. Preeclampsia is growing at a rapid rate - rate that exceeds diabetes and heart disease. Over half a million lives lost each year to preeclampsia. Women with a history of preeclampsia have 3-4 times the risk of high blood pressure. They also have double the risk for heart disease and stroke. Racial and ethnic disparities are present in preeclampsia. Black women are at higher risk of developing preeclampsia. They are also at much higher risk of dying from preeclampsia than other women. The reasons behind such disparities are unclear. What may explain these differences are social determinants of health. The contribution of social determinants to differences in preeclampsia is well recognized. However, a major gap in research remains strategies that address these factors. Our study will test a lifestyle intervention incorporating social risk factors to reduce the risk of preeclampsia.

Description:

Preeclampsia is a significant global health problem affecting over 10 million pregnancies each year. Preeclampsia disproportionately burdens ethnic minority women, especially African American women when compared to non-Hispanic white women. Once diagnosed with preeclampsia, African women are 3 times more likely to die of preeclampsia compared to their white counterparts. Evidence supports contribution of social risk factors towards racial and ethnic disparities seen with preeclampsia. However, currently, there are few trials that examine efficacy of social risks-focused lifestyle interventions on reduction of preeclampsia and its complications. This proposal is designed to address this crucial gap by testing feasibility (Aim 1), acceptability (Aim 1) and efficacy (Aim 2) of a social risks-focused lifestyle intervention to reduce preeclampsia in pregnant inner-city African American women. The intervention will be delivered via a randomized control trial design (N=100), with 6 monthly group sessions conducted in the second and third trimesters. The overall hypothesis is that the intervention will be feasible and acceptable, and that women randomized to the intervention group will have lower blood pressure and lower rates of preeclampsia compared with women receiving routine prenatal care.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 30, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• self-report as African-American/Non-Hispanic black

• residence in inner-city Milwaukee

• nulliparity

• gestational age at enrollment <=16 weeks

• able and willing to give informed consent

Exclusion Criteria:

• not able to communicate in English

• major fetal anomaly

• psychiatric illness that precludes group participation

Related Conditions & MeSH terms

• Pre-Eclampsia
• Preeclampsia

Intervention

Behavioral:
• SAIL
6 monthly group sessions with the study nurse with a background in prenatal care and the PI that will include each group will include preeclampsia education, coaching on stress management, resource navigation, and training in problem solving.

Locations

Country	Name	City	State
United States	Medical College of Wisconsin	Wauwatosa	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
Medical College of Wisconsin	American Heart Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retention	Retention will be measured by session attendance rates.	Post intervention measured at the completion of the last study visit, 3 years
Primary	Systolic and diastolic blood pressure: Post Intervention	BP will be taken by a study trained and certified research assistant using the study OMRON automated device.	Post intervention/at the last study visit, up to 40 weeks
Primary	Systolic and diastolic blood pressure: 6 Weeks Postpartum	BP will be taken by a study trained and certified research assistant using the study OMRON automated device.	At 6 weeks postpartum visit
Secondary	Preeclampsia	The rate of preeclampsia diagnosis will be compared between intervention and control group.	At the 6 weeks postpartum visit through patient interview, confirmed with medical record review